Cetuximab

Summary

Cetuximab (CHEMBL1201577) is an approved antibody (ATC L01FE01) targeting EGFR; indicated across 80 conditions including colorectal adenocarcinoma and head and neck squamous cell carcinoma; with CIViC clinical evidence for 264 variant-indication associations (e.g. BRAF V600E in colorectal cancer).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L01FE01
• Targets: 1 (EGFR)
• Indications: 80 conditions
• Clinical trials: 883
• Precision-oncology evidence (CIViC): 264 variant–indication associations

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201577
Name	Cetuximab
Type	Antibody
Max phase	4
ATC	L01FE01

Also known as: ABP-494, C-225, C225, Cetuximab, Cetuximab (genetical recombination), Cetuximab biosimilar (abp-494), CMAB-009, CMAB009, Erbitux, IMC-225, IMC-C225, MOAB C225

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
EGFR	epidermal growth factor receptor	Binding	9.41	17.5%	P00533

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): EGFR.

Top Reactome pathways

37 total, by targets touching each:

Pathway	Targets	Genes
Signaling by ERBB2	1	EGFR
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	1	EGFR
Signaling by ERBB4	1	EGFR
SHC1 events in ERBB2 signaling	1	EGFR
PLCG1 events in ERBB2 signaling	1	EGFR
PIP3 activates AKT signaling	1	EGFR
Signaling by EGFR	1	EGFR
GRB2 events in EGFR signaling	1	EGFR
GAB1 signalosome	1	EGFR
SHC1 events in EGFR signaling	1	EGFR
EGFR downregulation	1	EGFR
GRB2 events in ERBB2 signaling	1	EGFR
PI3K events in ERBB2 signaling	1	EGFR
EGFR interacts with phospholipase C-gamma	1	EGFR
EGFR Transactivation by Gastrin	1	EGFR
Constitutive Signaling by Aberrant PI3K in Cancer	1	EGFR
Signal transduction by L1	1	EGFR
Constitutive Signaling by EGFRvIII	1	EGFR
Inhibition of Signaling by Overexpressed EGFR	1	EGFR
RAF/MAP kinase cascade	1	EGFR
ERBB2 Regulates Cell Motility	1	EGFR
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	EGFR
ERBB2 Activates PTK6 Signaling	1	EGFR
Cargo recognition for clathrin-mediated endocytosis	1	EGFR
Clathrin-mediated endocytosis	1	EGFR
PTK6 promotes HIF1A stabilization	1	EGFR
Downregulation of ERBB2 signaling	1	EGFR
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	EGFR
Extra-nuclear estrogen signaling	1	EGFR
NOTCH3 Activation and Transmission of Signal to the Nucleus	1	EGFR

Dominant GO biological processes

GO term	Targets
cell morphogenesis	1
ossification	1
embryonic placenta development	1
positive regulation of protein phosphorylation	1
hair follicle development	1
ubiquitin-dependent protein catabolic process	1
signal transduction	1
cell surface receptor signaling pathway	1
epidermal growth factor receptor signaling pathway	1
salivary gland morphogenesis	1
learning or memory	1
positive regulation of cell population proliferation	1
gene expression	1
protein ubiquitination	1
cerebral cortex cell migration	1

Indications & clinical

Indications

80 indications (14 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
colorectal adenocarcinoma	4	MONDO:0005008	EFO:0000365
head and neck squamous cell carcinoma	4	MONDO:0010150	EFO:0000181
neoplasm	4	MONDO:0005070	EFO:0000616
squamous cell carcinoma	4	MONDO:0005096	EFO:0000707
upper aerodigestive tract neoplasm	4	MONDO:0005398	EFO:0004284
colorectal neoplasm	4	MONDO:0005335	EFO:0004142
head and neck cancer	4	MONDO:0005627	EFO:0006859
colorectal carcinoma	4	MONDO:0024331	EFO:1001951
head and neck neoplasm	4	MONDO:0005586	EFO:0005950
squamous cell lung carcinoma	4	MONDO:0005097	EFO:0000708
gastric adenocarcinoma	3	MONDO:0005036	EFO:0000503
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
carcinoma of esophagus	3	MONDO:0019086	EFO:0002916
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
rectal cancer	3	MONDO:0006519	EFO:1000657
gastric neoplasm	3	MONDO:0021085	EFO:0003897
esophageal squamous cell carcinoma	3	MONDO:0005580	EFO:0005922
colon carcinoma	3	MONDO:0002032	EFO:1001950
lung neoplasm	3	MONDO:0021117	MONDO:0008903
colonic neoplasm	3	MONDO:0005401	MONDO:0021063
laryngeal squamous cell carcinoma	3	MONDO:0005595	EFO:0006352
nasopharyngeal carcinoma	3	MONDO:0015459	MONDO:0015459
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
adenocarcinoma	2	MONDO:0004970	EFO:0000228
glioblastoma	2	MONDO:0018177	EFO:0000519
sarcoma	2	MONDO:0005089	EFO:0000691
carcinoma	2	MONDO:0004993	EFO:0000313
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
cervical carcinoma	2	MONDO:0005131	EFO:0001061
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
laryngeal neoplasm	2	MONDO:0021071	EFO:0003817
anus neoplasm	2	MONDO:0003046	EFO:0003835
oral cavity neoplasm	2	MONDO:0021245	EFO:0003868
breast neoplasm	2	MONDO:0021100	EFO:0003869
biliary tract neoplasm	2	MONDO:0005304	EFO:0003891
cholangiocarcinoma	2	MONDO:0019087	EFO:0005221
verrucous carcinoma	2	MONDO:0006006	EFO:0007535
oropharynx cancer	2	MONDO:0004608	EFO:1001931
lung adenocarcinoma	2	MONDO:0005061	EFO:0000571
skin neoplasm	2	MONDO:0002531	EFO:0004198
fallopian tube carcinoma	2	MONDO:0006206	EFO:1000251
peritoneal neoplasm	2	MONDO:0006901	EFO:1001100
hypopharyngeal carcinoma	2	MONDO:0005216	EFO:0002938
neuralgia	2	MONDO:0021667	EFO:0009430
complex regional pain syndrome	2	MONDO:0019369	EFO:1001998
ovarian cancer	2	MONDO:0008170	MONDO:0008170
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962
glioma	2	MONDO:0021042	MONDO:0100342
colon adenocarcinoma	2	MONDO:0002271	EFO:1001949
chordoma	2	MONDO:0008978	MONDO:0008978
bile duct carcinoma	2	MONDO:0005496	EFO:0005540
tongue cancer	2	MONDO:0004631	MONDO:0004631
salivary gland cancer	2	MONDO:0004669	MONDO:0004669
gallbladder neoplasm	2	MONDO:0021253	MONDO:0005411
adenoid cystic carcinoma	1	MONDO:0004971	EFO:0000231
anaplastic astrocytoma	1	MONDO:0016684	EFO:0002499
brain cancer	1	MONDO:0001657	MONDO:0001657
precancerous condition	1	MONDO:0021074	MONDO:0021074
pancreatic ductal adenocarcinoma	1	MONDO:0005184	MONDO:0005184

21 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 883.

Phase distribution

Phase	Trials
PHASE2	453
PHASE1	162
PHASE1/PHASE2	112
PHASE3	97
Not specified	39
PHASE2/PHASE3	9
EARLY_PHASE1	6
PHASE4	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05203172	PHASE4	RECRUITING	The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
NCT00327093	PHASE4	TERMINATED	Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
NCT01315990	PHASE4	UNKNOWN	FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
NCT01564810	PHASE4	UNKNOWN	Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
NCT02015650	PHASE4	TERMINATED	Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
NCT00956007	PHASE3	ACTIVE_NOT_RECRUITING	RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT01810913	PHASE2/PHASE3	RECRUITING	Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
NCT02999087	PHASE3	ACTIVE_NOT_RECRUITING	Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
NCT04008030	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04590963	PHASE3	ACTIVE_NOT_RECRUITING	Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04607421	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04776655	PHASE3	RECRUITING	Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
NCT04793958	PHASE3	ACTIVE_NOT_RECRUITING	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04892173	PHASE3	RECRUITING	JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04966481	PHASE3	RECRUITING	Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
NCT05063552	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05239741	PHASE3	ACTIVE_NOT_RECRUITING	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05253651	PHASE3	RECRUITING	A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05710406	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
NCT05863195	PHASE3	RECRUITING	Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT05948072	PHASE3	NOT_YET_RECRUITING	Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
NCT06064877	PHASE3	RECRUITING	A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06226857	PHASE3	RECRUITING	Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
NCT06589804	PHASE3	RECRUITING	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT06647563	PHASE3	NOT_YET_RECRUITING	Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
NCT06662786	PHASE3	RECRUITING	A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06706401	PHASE3	RECRUITING	Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
NCT06750094	PHASE3	RECRUITING	A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06997497	PHASE3	RECRUITING	A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06998069	PHASE3	RECRUITING	Head and Neck Cancer Study Project in the Geriatric Population
NCT07004413	PHASE3	NOT_YET_RECRUITING	Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07389265	PHASE3	RECRUITING	Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
NCT07432087	PHASE3	NOT_YET_RECRUITING	Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07441681	PHASE3	NOT_YET_RECRUITING	Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NCT07549399	PHASE3	NOT_YET_RECRUITING	SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
NCT00003809	PHASE3	COMPLETED	Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00004227	PHASE3	TERMINATED	Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
NCT00061815	PHASE3	COMPLETED	Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
NCT00063141	PHASE3	COMPLETED	Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
NCT00075686	PHASE3	COMPLETED	S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer

Clinical evidence (CIViC)

Variant × indication × effect (264 predictive associations from 374 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
BRAF V600E	Colorectal Cancer	Sensitivity/Response	Cetuximab + Encorafenib	CIViC A	EID9851
KRAS G12C	Colorectal Cancer	Sensitivity/Response	Cetuximab + Adagrasib	CIViC A	EID12063
KRAS Wildtype	Colorectal Cancer	Sensitivity/Response	Cetuximab + Chemotherapy	CIViC A	EID11262
KRAS Exon 2 Mutation	Colorectal Cancer	Resistance	Cetuximab	CIViC A	EID993 +1
KRAS Mutation	Colorectal Cancer	Resistance	Cetuximab + Panitumumab	CIViC A	EID5345
NRAS Mutation	Colorectal Cancer	Resistance	Panitumumab + Cetuximab	CIViC A	EID5344
BRAF V600E	Colorectal Cancer	Sensitivity/Response	Vemurafenib + Irinotecan + Cetuximab	CIViC B	EID1902 +1
EGFR Expression	Colorectal Cancer	Sensitivity/Response	Cetuximab	CIViC B	EID1572 +1
IDH1 R132	Glioblastoma	Sensitivity/Response	Cetuximab	CIViC B	EID3718 +1
KRAS G13D	Colorectal Cancer	Sensitivity/Response	Cetuximab	CIViC B	EID306 +1
AREG Expression	Colorectal Cancer	Sensitivity/Response	Cetuximab	CIViC B	EID788
BRAF Class 2 Mutations	Colorectal Cancer	Sensitivity/Response	Cetuximab + Panitumumab	CIViC B	EID7574
BRAF Class 3 Mutations	Colorectal Cancer	Sensitivity/Response	Cetuximab + Panitumumab	CIViC B	EID7575
BRAF Mutation	Colorectal Cancer	Sensitivity/Response	Panitumumab + Cetuximab	CIViC B	EID1404
BRAF V600	Colorectal Cancer	Sensitivity/Response	Vemurafenib + Cetuximab	CIViC B	EID1598
BRAF V600	Colorectal Cancer	Sensitivity/Response	Encorafenib + Cetuximab	CIViC B	EID6046
BRAF V600	Colorectal Cancer	Sensitivity/Response	Cetuximab + Encorafenib + Alpelisib	CIViC B	EID6047
BRAF V600	Colorectal Cancer	Sensitivity/Response	Cetuximab + Vemurafenib + Irinotecan	CIViC B	EID7355
BRAF V600E	Colorectal Cancer	Sensitivity/Response	Cetuximab + Nivolumab + Encorafenib	CIViC B	EID12624
BRAF V600E	Colorectal Cancer	Sensitivity/Response	Encorafenib + Binimetinib + Cetuximab	CIViC B	EID7260
BRAF V600E	Colorectal Cancer	Sensitivity/Response	Encorafenib + Cetuximab + Binimetinib	CIViC B	EID7612
BRAF Wildtype	Breast Cancer	Sensitivity/Response	Cetuximab	CIViC B	EID11657
BRAF Wildtype	Ovarian Cancer	Sensitivity/Response	Cetuximab	CIViC B	EID11663
BRAF Wildtype	Lung Non-small Cell Carcinoma	Sensitivity/Response	Cetuximab	CIViC B	EID11664
EGFR Amplification	Head And Neck Squamous Cell Carcinoma	Sensitivity/Response	Fluorouracil + Platinum Compound + Cetuximab	CIViC B	EID691
EGFR Amplification	Gastric Adenocarcinoma	Sensitivity/Response	Cetuximab	CIViC B	EID6927
EGFR Amplification	Colorectal Cancer	Sensitivity/Response	Cetuximab + Panitumumab	CIViC B	EID854
EGFR Amplification	Colorectal Cancer	Sensitivity/Response	Cetuximab	CIViC B	EID911
EGFR Overexpression	Head And Neck Squamous Cell Carcinoma	Sensitivity/Response	Cetuximab	CIViC B	EID692
EGFR Overexpression	Head And Neck Squamous Cell Carcinoma	Sensitivity/Response	Cetuximab + Docetaxel	CIViC B	EID849

+234 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

158 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR
SELUMETINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR
ABEMACICLIB	ChEMBL	Phase 4 (approved)	EGFR
ACALABRUTINIB	ChEMBL	Phase 4 (approved)	EGFR
AFATINIB DIMALEATE	ChEMBL	Phase 4 (approved)	EGFR
ALECTINIB	ChEMBL	Phase 4 (approved)	EGFR
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	EGFR
AXITINIB	ChEMBL	Phase 4 (approved)	EGFR
BACITRACIN	ChEMBL	Phase 4 (approved)	EGFR
BITHIONOL	ChEMBL	Phase 4 (approved)	EGFR
BOSUTINIB	ChEMBL	Phase 4 (approved)	EGFR
BRIGATINIB	ChEMBL	Phase 4 (approved)	EGFR
CABOZANTINIB	ChEMBL	Phase 4 (approved)	EGFR
CERITINIB	ChEMBL	Phase 4 (approved)	EGFR
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	EGFR
CHROMIC CHLORIDE	ChEMBL	Phase 4 (approved)	EGFR
CISPLATIN	ChEMBL	Phase 4 (approved)	EGFR
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	EGFR
COLISTIN	ChEMBL	Phase 4 (approved)	EGFR
CRIZOTINIB	ChEMBL	Phase 4 (approved)	EGFR
DACOMITINIB	ChEMBL	Phase 4 (approved)	EGFR
DASATINIB	ChEMBL	Phase 4 (approved)	EGFR
DOBUTAMINE	ChEMBL	Phase 4 (approved)	EGFR
DOCETAXEL	ChEMBL	Phase 4 (approved)	EGFR
EBASTINE	ChEMBL	Phase 4 (approved)	EGFR
ECONAZOLE	ChEMBL	Phase 4 (approved)	EGFR
ERLOTINIB	ChEMBL	Phase 4 (approved)	EGFR
FEDRATINIB	ChEMBL	Phase 4 (approved)	EGFR
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	EGFR
GEFITINIB	ChEMBL	Phase 4 (approved)	EGFR
GENTIAN VIOLET	ChEMBL	Phase 4 (approved)	EGFR
GILTERITINIB	ChEMBL	Phase 4 (approved)	EGFR
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	EGFR
IBRUTINIB	ChEMBL	Phase 4 (approved)	EGFR
IMATINIB	ChEMBL	Phase 4 (approved)	EGFR
LAPATINIB	ChEMBL	Phase 4 (approved)	EGFR
LAPATINIB DITOSYLATE	ChEMBL	Phase 4 (approved)	EGFR
LAZERTINIB	ChEMBL	Phase 4 (approved)	EGFR
LEVODOPA	ChEMBL	Phase 4 (approved)	EGFR
LORLATINIB	ChEMBL	Phase 4 (approved)	EGFR
METHYLDOPA	ChEMBL	Phase 4 (approved)	EGFR
MICONAZOLE	ChEMBL	Phase 4 (approved)	EGFR
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	EGFR
MITOXANTRONE	ChEMBL	Phase 4 (approved)	EGFR
MOBOCERTINIB	ChEMBL	Phase 4 (approved)	EGFR
MONTELUKAST	ChEMBL	Phase 4 (approved)	EGFR
NELFINAVIR	ChEMBL	Phase 4 (approved)	EGFR
NERATINIB	ChEMBL	Phase 4 (approved)	EGFR
NICLOSAMIDE	ChEMBL	Phase 4 (approved)	EGFR
OLMUTINIB	ChEMBL	Phase 4 (approved)	EGFR
OSIMERTINIB	ChEMBL	Phase 4 (approved)	EGFR
PERHEXILINE	ChEMBL	Phase 4 (approved)	EGFR
PONATINIB	ChEMBL	Phase 4 (approved)	EGFR
SORAFENIB	ChEMBL	Phase 4 (approved)	EGFR
SULOCTIDIL	ChEMBL	Phase 4 (approved)	EGFR
SUNITINIB	ChEMBL	Phase 4 (approved)	EGFR
TAMOXIFEN	ChEMBL	Phase 4 (approved)	EGFR
TERFENADINE	ChEMBL	Phase 4 (approved)	EGFR
THIORIDAZINE	ChEMBL	Phase 4 (approved)	EGFR
TRIBROMSALAN	ChEMBL	Phase 4 (approved)	EGFR